Sienna Biopharmaceuticals, Inc.’s $20 Million Common Stock Offering

Davis Polk advised the joint book-running managers in connection with a $20 million SEC-registered common stock offering by Sienna Biopharmaceuticals, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “SNNA.”

Cowen and BMO Capital Markets acted as underwriters in the deal.

Based in Westlake Village, California, Sienna Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of targeted, topical products in medical dermatology and aesthetics.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture), counsel Jason Bassetti and associate Josephine Chen. The tax team included partner Rachel D. Kleinberg and associate Joseph M. Gerstel. The intellectual property and technology team included associate Yifu Chen.

Involved fees earner: Jason Bassetti – Davis Polk & Wardwell; Josephine Chen – Davis Polk & Wardwell; Yifu Chen – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Joseph Gerstel – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: BMO Capital Markets; Cowen and Company;


Author: Ambrogio Visconti